Johnson & Johnson's earnings call highlights strong performance, driven by growth in consumer and emerging markets, offset by generic competition impacting certain pharmaceutical segments.  Elevated concerns about currency fluctuations impacting the bottom line in Q4.  Management expresses confidence in the business's long-term prospects, despite short-term headwinds.
[1]
